Poolbeg secures exclusive licence to possible obesity drug tech
14th Dec 2022 16:14
(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.
Read morePoolbeg announces 'breakthrough' in AI drug target programme
8th Nov 2022 13:06
(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).
Read morePoolbeg Pharma upbeat on US patent application progress
4th Oct 2022 14:14
(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.
Read morePoolbeg inks exclusive deal for melioidosis vaccine candidate
21st Sep 2022 16:18
(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.
Read morePoolbeg granted European patent for antiviral nose spray
14th Apr 2022 14:53
(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.
Read morePoolbeg signs option deal for potential melioidosis vaccine
6th Dec 2021 15:23
(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an option agreement to licence 'MelioVac', a vaccine for melioidosis, with University College Dublin and its inventor Siobhán McClean, it announced on Monday, through the university's intellectual property office NovaUCD.
Read morePoolbeg adds Daniel Hoft to scientific advisory board
25th Nov 2021 12:12
(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg announced the appointment of Daniel Hoft to its scientific advisory board on Thursday.
Read moreNew patents filed to protect Poolbeg disease prediction platform
14th Oct 2021 16:10
(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma updated the market on new patent filings for its 'PredictViral' platform - which estimates disease severity and contagiousness in people who are recently infected with a respiratory virus - on Thursday.
Read more